Abstract: Objective To explore the clinical efficacy of recombinant human endostatin (en-dostar)combined with three dimensional conformal radiotherapy (3D-CRT)on treatment of patients with non-small cell lung cancer (NSCLC).Methods 78 patients with NSCLC in phase ⅢA ~ⅢB by histopathology and cytology were randomly divided into control group (treated with single 3D-CRT) and experiment group (treated with endostar and 3D-CRT),39 cases in each group.Clinical efficacy and adverse responses were evaluated after two cycles of treatment and survival time was observed until the end of follow-up.Results The objective remission rate (RR)and disease control rate (DCR)in experiment group were 69.2% and 89.7% respectively,which were evidently higher than the 33.3%and 71.8% in control group (P <0.05 or P <0.01).The main adverse responses in both groups were anemia,nausea and vomiting,leukopenia and radioactive lung injury and all were tolerable.Until the end of follow-up,the medium progression free survival time and medium survival time in experimental group were 8 and 13 months,and in control group were 5 and 9 months respectively.Conclusion Endostar combined with 3D-CRT are superior to single 3D-CRT without increasing adverse responses in the treatment of NSCLC.